HeXun Biosciences Co (ROCO:6986) ROC (Joel Greenblatt) %: 70.13% (As of Mar. 2026) — 115% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6986 HeXun Biosciences Co Ltd ROCO:6986
22 GF Score
Price NT$43.70
! 2 Warning Signs
View Full Analysis

What is HeXun Biosciences Co ROC (Joel Greenblatt) %?

HeXun Biosciences Co ROCO:6986 22 ROC (Joel Greenblatt) % is 70.13% as of Mar. 2026, which is 115% above its 10-year median of 32.63. GuruFocus rates ROCO:6986 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,322 Biotechnology companies, HeXun Biosciences Co ranks better than 89.79% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. HeXun Biosciences Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 70.13%.

The historical rank and industry rank for HeXun Biosciences Co's ROC (Joel Greenblatt) % or its related term are showing as below:

ROCO:6986' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -36.09   Med: 32.63   Max: 125.26
Current: 75.42

During the past 6 years, HeXun Biosciences Co's highest ROC (Joel Greenblatt) % was 125.26%. The lowest was -36.09%. And the median was 32.63%.

ROCO:6986's ROC (Joel Greenblatt) % is ranked better than
89.79% of 1322 companies
in the Biotechnology industry
Industry Median: -291.605 vs ROCO:6986: 75.42

HeXun Biosciences Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


HeXun Biosciences Co  (ROCO:6986) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


HeXun Biosciences Co ROC (Joel Greenblatt) % Related Terms


HeXun Biosciences Co ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for HeXun Biosciences Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeXun Biosciences Co ROC (Joel Greenblatt) % Chart

HeXun Biosciences Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -36.09 -3.52 32.63 125.26 77.39

HeXun Biosciences Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.45 101.74 33.60 90.95 70.13

ROCO:6986 vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, HeXun Biosciences Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HeXun Biosciences Co ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where HeXun Biosciences Co's ROC (Joel Greenblatt) % falls into.


ROCO:6986
22GF Score
HeXun Biosciences Co Ltd ROCO:6986
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeXun Biosciences Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(74.181 + 6.017 + 19.406) - (43.563 + 0 + 15.027)
=41.014

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(72.033 + 8.635 + 15.484) - (41.096 + 0 + 3.843)
=51.213

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of HeXun Biosciences Co for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=135.148/( ( (148.216 + max(41.014, 0)) + (144.967 + max(51.213, 0)) )/ 2 )
=135.148/( ( 189.23 + 196.18 )/ 2 )
=135.148/192.705
=70.13 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 70.13% mean?
HeXun Biosciences Co (ROCO:6986) has a ROC (Joel Greenblatt) % of 70.13% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on HeXun Biosciences Co and its competitors. This is 115% above median its historical median of 32.63. According to the industry distribution chart, HeXun Biosciences Co ranks #135 out of 1322 companies in the Biotechnology industry, placing it in the top 10.2%.
Is HeXun Biosciences Co's ROC (Joel Greenblatt) % too high?
HeXun Biosciences Co's current ROC (Joel Greenblatt) % of 70.13% is 115% above median its 10-year median of 32.63. Based on the distribution chart, HeXun Biosciences Co ranks #135 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HeXun Biosciences Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HeXun Biosciences Co ranks #135 out of 1322 companies for ROC (Joel Greenblatt) %. This places HeXun Biosciences Co in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on HeXun Biosciences Co and its competitors. HeXun Biosciences Co's current ROC (Joel Greenblatt) % is 70.13%, which is 115% above median its own 10-year median of 32.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current ROC (Joel Greenblatt) % of 70.13%. The current ROC (Joel Greenblatt) % is 70.13%, which is 115% above median its 10-year median of 32.63. HeXun Biosciences Co's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current ROC (Joel Greenblatt) % is 70.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeXun Biosciences Co Business Description

Address Chunri Road, 6 F., No. 1490, Taoyuan District, Taoyuan, TWN
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
22GF Score

Get the complete analysis for ROCO:6986

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$43.70
Price